Hussein A Rajab1, Nathaniel L Baker2, Kelly J Hunt2, Richard Klein3, Patricia A Cleary4, John Lachin4, Gabriel Virella5, Maria F Lopes-Virella6. 1. Department of Medicine, Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, SC, USA. 2. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. 3. Department of Medicine, Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA. 4. The Biostatistics Center, George Washington University, Washington DC, Washington DC, USA. 5. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA. 6. Department of Medicine, Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, USA. Electronic address: virellam@musc.edu.
Abstract
AIMS: This study was undertaken to determine whether levels of inflammation and endothelial dysfunction biomarkers in serum samples collected at baseline in the Diabetes Control and Complications Trial (DCCT) cohort could predict the development of retinopathy. METHODS: Levels of clotting/fibrinolysis, inflammation and endothelial dysfunction biomarkers were measured in 1391 subjects with type 1 diabetes to determine whether their levels predicted increased risk to develop or accelerate progression of retinopathy during 16years of follow-up. RESULTS: Using regression models adjusted for DCCT treatment group, duration of diabetes, baseline retinopathy scores, HbA1c and albumin excretion rate, the baseline levels of sE-selectin and PAI-1 (active) were significantly associated with increased risk of a 3-step progression in retinopathy score in the primary prevention cohort (PPC). After adjusting for additional covariates (e.g., ACE/ARB and statin therapy), this association persisted. Levels of active and total PAI-1 in the same group were also significantly associated, after similar adjustments, with the time to progress to severe non-proliferative retinopathy during the follow-up period (54 and 29%, respectively of increased risk). No associations were observed in the secondary intervention cohort for any of the outcomes. CONCLUSIONS: High levels of sE-selectin and PAI-1 are associated with the development of retinopathy in patients with uncomplicated type 1 diabetes. Published by Elsevier Inc.
AIMS: This study was undertaken to determine whether levels of inflammation and endothelial dysfunction biomarkers in serum samples collected at baseline in the Diabetes Control and Complications Trial (DCCT) cohort could predict the development of retinopathy. METHODS: Levels of clotting/fibrinolysis, inflammation and endothelial dysfunction biomarkers were measured in 1391 subjects with type 1 diabetes to determine whether their levels predicted increased risk to develop or accelerate progression of retinopathy during 16years of follow-up. RESULTS: Using regression models adjusted for DCCT treatment group, duration of diabetes, baseline retinopathy scores, HbA1c and albumin excretion rate, the baseline levels of sE-selectin and PAI-1 (active) were significantly associated with increased risk of a 3-step progression in retinopathy score in the primary prevention cohort (PPC). After adjusting for additional covariates (e.g., ACE/ARB and statin therapy), this association persisted. Levels of active and total PAI-1 in the same group were also significantly associated, after similar adjustments, with the time to progress to severe non-proliferative retinopathy during the follow-up period (54 and 29%, respectively of increased risk). No associations were observed in the secondary intervention cohort for any of the outcomes. CONCLUSIONS: High levels of sE-selectin and PAI-1 are associated with the development of retinopathy in patients with uncomplicated type 1 diabetes. Published by Elsevier Inc.
Entities:
Keywords:
Biomarkers; Diabetes complications; E-selectin; Plasminogen activator inhibitor type 1; Retinopathy; Type 1 diabetes
Authors: F C Barouch; K Miyamoto; J R Allport; K Fujita; S E Bursell; L P Aiello; F W Luscinskas; A P Adamis Journal: Invest Ophthalmol Vis Sci Date: 2000-04 Impact factor: 4.799
Authors: Toru Abiko; Atsuko Abiko; Allen C Clermont; Brett Shoelson; Naoichi Horio; Junichi Takahashi; Anthony P Adamis; George L King; Sven-Erik Bursell Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Miranda T Schram; Nish Chaturvedi; Casper Schalkwijk; Francesco Giorgino; Pertti Ebeling; John H Fuller; Coen D Stehouwer Journal: Diabetes Care Date: 2003-07 Impact factor: 19.112
Authors: Timothy J Lyons; Alicia J Jenkins; Deyi Zheng; Daniel T Lackland; Daniel McGee; W Timothy Garvey; Richard L Klein Journal: Invest Ophthalmol Vis Sci Date: 2004-03 Impact factor: 4.799
Authors: Alicia J Jenkins; Mugdha V Joglekar; Anandwardhan A Hardikar; Anthony C Keech; David N O'Neal; Andrzej S Januszewski Journal: Rev Diabet Stud Date: 2015-08-10
Authors: Amy E Millen; Michelle W Sahli; Jing Nie; Michael J LaMonte; Pamela L Lutsey; Barbara E K Klein; Julie A Mares; Kirstin J Meyers; Christopher A Andrews; Ronald Klein Journal: Cardiovasc Diabetol Date: 2016-09-01 Impact factor: 9.951
Authors: Fernando Korn Malerbi; Caio Vinicius Regatieri; João Roberto de Sa; Paulo Henrique Morales; Michel Eid Farah; Sergio Atala Dib Journal: Int J Retina Vitreous Date: 2017-12-18